Successful Desensitization of a Patient with Rituximab Hypersensitivity

الملخص EN

Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies.

Rituximab causes hypersensitivity reactions during infusions.

The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab.

We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization.

In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.